Mesoblast Limited (MESO)’s Ryoncil® Gains U.S.-Origin Status, Avoids Import Tariffs

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. Mesoblast Limited is one of them.

Mesoblast Limited (NASDAQ:MESO) is a global leader in developing allogeneic, off-the-shelf cellular medicines for inflammatory diseases. Using its proprietary mesenchymal lineage cell platform, the company targets severe and life-threatening conditions by modulating immune responses and promoting tissue repair. Its lead product, Ryoncil® (remestemcel-L), recently became the first FDA-approved allogeneic mesenchymal stromal cell therapy for pediatric patients with steroid-refractory acute graft versus host disease (SR-aGvHD). MESO is among the stocks with insider buying.

In late September 2025, Mesoblast Limited (NASDAQ:MESO) reaffirmed that all its cell therapy products, including Ryoncil®, are manufactured from U.S. donors in the United States and officially designated as U.S.-origin products. This designation exempts them from pharmaceutical import tariffs, giving the firm a significant commercial edge while underscoring its commitment to U.S.-based manufacturing and regulatory compliance.

Mesoblast Limited (MESO)’s Ryoncil® Gains U.S.-Origin Status, Avoids Import Tariffs

Looking ahead, MESO is advancing the commercial launch of Ryoncil® while also progressing regulatory pathways for other therapies. Its Biologic License Application for Revascor®, aimed at treating ischemic heart failure, is under FDA review. At the same time, the business is expanding the development of rexlemestrocel-L for chronic conditions such as heart failure and low back pain.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.